Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial

20250 citationsJournal Articlehybrid Open Access

Authors

Hideki Koizumi · University of the Ryukyus

Shigeru Honda · Osaka Metropolitan University

Tsutomu Yasukawa · Nagoya City University

Genichiro Kishino · Aizawa Hospital

Tetsuju Sekiryu · Fukushima Medical University

Andrea Schulze · Bayer (Germany)

Takuto Yamashita ·

Abstract

Aflibercept 8 mg has similar efficacy and safety to aflibercept 2 mg when administered at extended dosing intervals in both the Japan and non-Japan subgroups, consistent with the overall PULSAR results.

Topics & Keywords

Retinal Diseases and Treatments Ophthalmology and Visual Impairment Studies Retinal Imaging and Analysis

Publication Details

Published in: Japanese Journal of Ophthalmology

Volume 70, Issue 1, pp. 139-149

DOI: 10.1007/s10384-025-01270-8

Field-Weighted Citation Impact: 0.00

Command Palette

Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial

Authors

Abstract

Topics & Keywords

Publication Details